Public debt: Do not let it eclipse the fiscal deficit
Mint Bangalore|January 06, 2025
The Centre's plan to adopt debt as its new focus for budget prudence after 2025-26 does hold merit but we must not lose track of the fiscal gap. It'll remain a valuable economic indicator

In a 2020 address to the nation soon after the outbreak of covid, Prime Minister Narendra Modi cited age-old wisdom that advised against losing control of three things: fire, debt and disease. To cushion India's economy from the pandemic's shock, though, government spending had to vastly exceed its inflows, taking its fiscal deficit to 9% plus of GDP in 2020-21. The reversal of this debt-raising fiscal expansion since then has followed a glide path with 4.5% as the fisc's aim, to be achieved by the next Union budget for 2025-26. As no further target for it has been set, the Fiscal Responsibility and Budget Management (FRBM) Act's goal of 3% looks likely to keep gathering dust. Signalling a shift in approach, the last budget revealed an intent to target the level of public debt, rather than the annual fisc, in subsequent years as a way to keep overspending in check. This conforms with the PM's prudent advice of 2020, but what exactly does it imply?

Diese Geschichte stammt aus der January 06, 2025-Ausgabe von Mint Bangalore.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der January 06, 2025-Ausgabe von Mint Bangalore.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS MINT BANGALOREAlle anzeigen
Mint Bangalore

Nvidia Shows New Chips, Inks Toyota Deal for Robotic Cars

Shares of Toyota, Nvidia's suppliers rise on optimism about the AI chip maker's prospects

time-read
3 Minuten  |
January 08, 2025
Mint Bangalore

DIAL drops plea over Hindon ops expansion

Delhi International Airport Ltd (DIAL) on Tuesday withdrew its legal challenge against the Centre's decision to allow the Airports Authority of India (AAI) to operate scheduled commercial flights from the Indian Air Force Station in Hindon, Ghaziabad.

time-read
1 min  |
January 08, 2025
Mint Bangalore

Auto sales rise 9% in 2024 despite headwinds: Fada

Inventory build-up, delayed harvest payments, weak consumer sentiment weighed on demand in Dec

time-read
1 min  |
January 08, 2025
Mint Bangalore

Razorpay Charts Return to India; Eyes Expansion, IPO

Firm is likely to complete its reverse-flip in six months, with an IPO expected in two years

time-read
3 Minuten  |
January 08, 2025
Mint Bangalore

Bank profits set to moderate in FY26 as bad assets rise

Ind-Ra sharply revised down its FY25 system credit growth estimate to 13-13.5% from 15% earlier

time-read
2 Minuten  |
January 08, 2025
Mint Bangalore

Lloyds Metals shines on likely gains from acquisition, capex

Lloyds Metals & Energy Ltd's shares have gained about 15% so far in 2025 after the company's quarterly update and announcement of employee stock options (Esops) for its 6,000 workers.

time-read
1 min  |
January 08, 2025
Mint Bangalore

Another tough year for FMCG?

Feeling blue

time-read
2 Minuten  |
January 08, 2025
Mint Bangalore

Your fancy, new ETF might be a little too fancy

Exchange-traded funds have mostly been great investments, but they are getting too complex for their own good

time-read
4 Minuten  |
January 08, 2025
Mint Bangalore

Risks to economy escalating in 2025, cautions SBICAPS

Rising household debt, fluctuating FII flows among risks that threaten to amplify economic fragility: Report

time-read
1 min  |
January 08, 2025
Mint Bangalore

Intas Pharma bags another overseas company

Gujarat-based drug-maker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek, and Abu Dhabi Investment Authority (ADIA) as its investors, has signed a deal to acquire a biologic medication brand from US-based Coherus Biosciences.

time-read
1 min  |
January 08, 2025